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Abstract  
Recently, the insulin-sensitizing adipokine adiponectin and the insulin resistance-inducing 
adipokine tumor necrosis factor- (TNF-) were reported to inhibit each other’s production in 
adipocytes. We investigated the effects of two 3-adrenoceptor agonists, 5-[(2R)-2-[[(2R)-2- 
(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316,243) 
and (±)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid 
(BRL37344), on the gene expression of adiponectin, two adiponectin receptors, and TNF-in 
adipose tissues of C57BL/6J mice. CL-316,243 and BRL37344 downregulated adiponectin, but 
upregulated adiponectin receptor 2 (not receptor 1) in epididymal or/and subcutaneous white 
adipose tissues and in brown adipose tissue. TNF-expression was upregulated only in epididymal 
adipose tissue. To further explore these effects, we treated differentiated 3T3-L1 adipocytes with 
the non-selective -adrenoceptor agonist isoproterenol. As a result, adiponectin receptor 2 (but not 
receptor 1) gene expression and TNF- protein expression increased, but gene expression and 
secretion of adiponectin decreased. The upregulation of adiponectin receptor 2 by isoproterenol is 
most likely via 2,3-adrenoceptors, adenylyl cyclases, and protein kinase A (PKA). However, the 
accompanying activation of AMP-activated protein kinase (AMPK) may inhibit this upregulation. 
Our results suggest that upregulation of TNF- and downregulation of adiponectin by 
-adrenoceptor activation may contribute to the pathogenesis of catecholamine-induced insulin 
resistance, and that upregulation of adiponectin receptor 2 may be a feedback result of reduced 
adiponectin. 
 
Keywords: -adrenoceptor; Adiponectin; Adiponectin receptor; Tumor necrosis factor-; 3T3-L1 
adipocyte; Adipose tissue; Catecholamine; Insulin resistance  
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1. Introduction 
 
White adipose tissue is a key regulator of whole-body energy metabolism, playing a central 
role in the balance between energy storage and energy mobilization. Brown adipose tissue is 
specific for metabolic heat production. In rodent adipose tissues, -adrenoceptors, predominantly 
3-adrenoceptors, are expressed. They mediate the major effects of adrenaline and noradrenaline, 
such as stimulating lipolysis in white adipose tissue and thermogenesis in brown adipose tissue. 
Regional differences exist between visceral and subcutaneous white adipose tissues. Visceral fat 
tissue is known to be lipolytically active in response to catecholamines compared to subcutaneous 
tissue (Lafontan and Berlan, 2003). 
In recent years, it has been demonstrated that adipocytes also secrete biologically active 
molecules called adipokines. Among them, adiponectin and tumor necrosis factor- (TNF- are 
two important adipokines that antagonistically influence insulin sensitivity. TNF- is thought to be 
a causative factor of insulin resistance in fat tissue, involving insulin receptor autophosphorylation 
and insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation (Hotamisligil and Spiegelman, 
1994; Hotamisligil et al., 1994, 1996). Adiponectin is a recently discovered insulin-sensitizing 
adipokine composed of an N-terminal collagenous domain and a C-terminal globular domain. In 
plasma it can exist as full-length adiponectin or globular domain adiponectin (Kadowaki and 
Yamauchi, 2005; Kadowaki et al., 2006; Fruebis et al., 2001; Yamauchi et al., 2001). Adiponectin 
stimulates fatty acid oxidation and glucose transport in muscle and inhibit gluconeogenesis in liver 
by activating AMP-activated protein kinase (AMPK) (Yamauchi et al., 2002). TNF-and 
adiponectin are reported to mutually inhibit each other’s production in adipose tissue (Maeda et al., 
2001, 2002; Fasshauer et al., 2002). 
Adiponectin receptor 1 and 2 mediate most effects of adiponectin. Adiponectin receptor 1, which 
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is a high-affinity receptor for globular domain adiponectin and a very low-affinity receptor for 
full-length adiponectin, is most abundantly expressed in skeletal muscle. Adiponectin receptor 2, 
which serves as a moderate-affinity receptor for both forms of adiponectin, predominates in liver 
(Yamauchi et al., 2003). Interestingly, both of these receptors are also expressed in adipocytes, 
where adiponectin itself is expressed and secreted (Fasshauer et al., 2004). A recent report suggests 
that adiponectin acts as an autocrine factor in adipocytes (Fu et al., 2005).  
Studies demonstrate that -adrenoceptor agonists decrease adiponectin gene expression via 
activation of a Gs-protein-PKA-dependent pathway (Fasshauer et al., 2001) in 3T3-L1 adipocytes 
and in white adipose tissue (Delporte et al., 2002).  At the present time, however, little is known 
about the effects of -adrenoceptor agonists on the regulation of adiponectin receptors and 
TNF-in adipose tissues. Only a single study has reported that chronic treatment of diabetic 
(db/db) micewith-adrenoceptor agonist increased adiponectin levels and decreased insulin levels 
in plasma, but left adiponectin receptors in adipose tissues unchanged (Oana et al., 2005). These 
results may only reflect the indirect effects of -adrenoceptor agonists as altered insulin levels 
(Tsuchida et al., 2004) could, in turn, regulate adiponectin receptors. The direct influences of 
-adrenoceptor agonists on adiponectin receptors are still unknown. In the present study, we 
examined the acute pharmacological effects of β-adrenoceptor agonists on adiponectin, adiponectin 
receptors and TNF- expression in white and brown adipose tissues of lean mice in vivo and in 
differentiated 3T3-L1 adipocytes in vitro. 
 
2. Materials and Methods 
 
2.1. Materials 
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Dulbecco’s modified Eagle’s medium and fetal bovine serum were purchased from Gibco 
(Rockville, MD). H-89 and compound C were obtained from D. Western Therapeutics Institute, Inc. 
(Nagoya, Japan) and Calbiochem (La Jolla, CA), respectively. The following chemicals were 
purchased from Sigma Chemical Co. (St. Louis, MO): 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2- 
hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316,243), (±)-(R*,R*)-[4-[2- 
[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid (BRL37344), isoproterenol, 
dobutamine, fenoterol, forskolin, 5-aminoimidazole-4-carboxamide-riboside (AICAR), insulin, 
isobutylmethylxanthine and dexamethasone. 
 
2.2. Animals and treatments 
 
Twenty-three male C57BL/6J mice aged 10 weeks were obtained from Charles River Labs 
(Tokyo, Japan) and were fasted for 8 h before the experiments began. 
Mice were injected with -adrenoceptor agonist CL-316,243 (n=8) or BRL37344 (n=7) 
subcutaneously at a dose of 2 mg/kg of body weight. A second dose was given eight hours later. 
Control mice (n=8) received vehicle (0.9% saline) only. 
Sixteen hours after the first injection, all mice were sacrificed by diethyl ether overdose. 
Epididymal and inguinal white adipose tissue, as well as interscapular brown adipose tissue were 
immediately removed, frozen in liquid nitrogen, and stored at -80°C until extraction of RNA.  
All procedures involving animals were approved by the Animal Care and Use Committee of 
University of Tsukuba. Moreover, the protocols complied with European Community guidelines for 
the use of experimental animals. 
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2.3. Cell culture and differentiation 
 
3T3-L1 preadipocytes (American Type Culture Collection, Rockville, MD) were grown at 37 °C 
in 5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum (minimal 
medium). Two days after reaching confluence, preadipocytes were cultured for 48 h in minimal 
medium further supplemented with 1.7 μM insulin, 0.5 mM isobutylmethylxanthine, and 1 μM 
dexamethasone to induce differentiation. After culturing another 48 h in minimal medium 
supplemented only with 1.7 μM insulin, cells were refed with minimal medium for 4 days. At the 
time of the experiments, more than 90% of the cells had accumulated fat droplets as determined by 
Oil Red O staining. Adipocytes were maintained for 6 h in serum-free medium before various 
effectors were added. 
 
2.4. Quantitative real-time PCR 
 
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA), and 1 μg of total 
RNA was reverse transcribed into cDNA using the RNA PCR kit (TaKaRa Bio Inc., Shiga, Japan) 
according to the manufacturer’s instructions. 
Quantitative real-time PCR was performed using ABI PRISM 7900 Sequence Detector, TaqMan 
Universal PCR Master MIX and Assays-on-Demand Gene Expression Assay MIX (Product No. 
adiponectin: Mm00456425ml, adiponectin receptor 1: Mm01291334mH, adiponectin receptor 2: 
Mm00815950ml, TNF-: Mm00443258ml and 18S rRNA: 4308329) (Applied Biosystems, Foster 
City, CA). The thermal cycling protocol was 2 min at 50 °C and 10 min at 95 °C, followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min. Adiponectin, adiponectin receptor 1, adiponectin 
receptor 2, and TNF- mRNA levels were normalized to those of 18S rRNA. 
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2.5. Assays for intracellular cAMP, adiponectin release and TNF- protein level 
 
Intracellular cAMP, released adiponectin in culture medium, and TNF- protein levels were 
measured using ELISA kits from Amersham Biosciences (Amersham, UK), Otsuka Pharmaceutical 
(Tokyo, Japan) and eBiosciences (San Diego, CA),
 
respectively, according to the manufacturers’ 
instructions.  
 
2.6. Western blots 
 
Cells were lysed with cell lysis buffer (Cell Signaling Technology, Inc., Beverly, MA). Lysates 
were analyzed by Western blot using either anti-phospho-AMPK antibody (Thr172) or AMPK 
antibody (Cell Signaling Technology, Inc., Beverly, MA).  
 
2.7. Statistical analysis 
 
Results are expressed as the mean ± S.E.M. Significance was assessed by ANOVA with the 
Dunnett’s test. P values <0.05 were considered significant and <0.01 highly significant. 
 
3. Results 
 
3.1.-adrenoceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 
and TNF- in adipose tissues of C57BL/6J mice  
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As3-adrenoceptor is the predominant subtype of -adrenoceptors expressed in rodent 
adipocytes, we investigated the effects of two3-adrenoceptor agonists, CL-316,243 and 
BRL37344, on adiponectin, adiponectin receptor, and TNF-gene expression in adipose tissues of 
C57BL/6J mice in vivo. 
Steady-state adiponectin mRNA levels in epididymal white adipose tissue were 2.3-fold higher 
than that of subcutaneous white adipose tissue and 3-fold higher than that of brown adipose tissue. 
When we measured levels from the CL-316,243-treatment group, adiponectin gene expression was 
significantly reduced in epididymal white adipose tissue and brown adipose tissue by 52% and 56%, 
respectively, as compared to the control group (P<0.01). In the BRL37344-treatment group, 
adiponectin mRNAs were decreased by 31% in subcutaneous white adipose tissue (P<0.05) and by 
46% in brown adipose tissue (P<0.01) (Fig. 1A). 
Adiponectin receptor 1 gene expression in subcutaneous white adipose tissue was less than in 
epididymal white adipose tissue and brown adipose tissue. Treatment with3-adrenoceptor agonists 
did not affect expression in any group (Fig. 1B). 
Adiponectin receptor 2 mRNAs, however, were upregulated in subcutaneous white adipose tissue 
and brown adipose tissue in the CL-316,243-treatment group (2.3-fold, P<0.01 and 2.2-fold, 
P<0.05, respectively). In the BRL37344-treatment group, adiponectin receptor 2 mRNAs were 
increased in epididymal white adipose tissue (1.8-fold, P<0.01), subcutaneous white adipose tissue 
(2.0-fold, P<0.01) and brown adipose tissue (2.9-fold, P<0.01) (Fig. 1C). 
Steady-state TNF- mRNA levels in subcutaneous white adipose tissue were notably higher than 
those in epididymal white adipose tissue and brown adipose tissue. TNF- mRNAs were 
upregulated in epididymal white adipose tissue in the CL-316,243-treatment group (8.9-fold, 
P<0.05) and in the BRL37344-treatment group (14.5-fold, P<0.01) (Fig. 1D).  
 9 
 
3.2. Non-selective-adrenoceptor agonist isoproterenol downregulates adiponectin, but 
upregulates adiponectin receptor 2 and TNF- in differentiated 3T3-L1 adipocytes 
 
The in vivo data led us to speculate that -adrenoceptor agonists could downregulate adiponectin 
while upregulating adiponectin receptor 2 and TNF- gene expression in adipocytes. To test this 
hypothesis in vitro, we added the non-selective -adrenoceptor agonist isoproterenol to 
differentiated 3T3-L1 adipocytes.  
Treatment of 3T3-L1 adipocytes with 10 M isoproterenol for 16 h reduced the level of 
adiponectin mRNA by 50% (P<0.01). Treatment did not change adiponectin receptor 1 levels, but it 
upregulated adiponectin receptor 2 gene expression 2.2-fold (P<0.01) (Fig. 2A). Suppressed 
adiponectin and elevated adiponectin receptor 2 mRNA levels were significant after 8 h and 
persisted for up to 24 h after 10 M isoproterenol treatment (P<0.01) (Fig. 2B). 
Treatment with isoproterenol for 24 h decreased adiponectin release by about 30% (Fig. 2C), but 
increased TNF- protein expression by about 50% (Fig. 2D). Adiponectin receptor 2 protein 
expression, TNF-mRNA expression and the amount of TNF- released into the medium were 
too low to measure accurately.  
 
3.3 2,3-adrenoceptor agonists upregulate adiponectin receptor 2 in differentiated 3T3-L1 
adipocytes 
 
To determine which subtype(s) of -adrenoceptor mediated the effect of isoproterenol on 
adiponectin receptor 2 gene expression, different subtype-specific -adrenoceptor agonists were 
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tested. The 1-adrenoceptor agonist dobutamine was without effect, while the 2-adrenoceptor 
agonist fenoterol and 3-adrenoceptor agonists CL-316,243 and BRL37344 (10 M) each 
significantly enhanced adiponectin receptor 2 mRNA expression by about 2-fold (P<0.01) after 16 
h treatment (Fig. 3A). These stimulatory effects of 2,3-adrenoceptor agonists were statistically 
significant at concentrations as low as 100 nM. However, none of the selective -adrenoceptor 
agonists affected adiponectin receptor 1 gene expression (data not shown).  
 
3.4. Isoproterenol stimulates adiponectin receptor 2 mainly via adenylyl cyclase and PKA 
 
Typically, the main signaling pathway of -adrenoceptors leads to activation of Gs-proteins that, 
in turn, activate adenylyl cyclases for cAMP generation. This second messenger then activates 
protein kinase A (PKA). To look for activation of adenylyl cyclases, we measured cAMP levels 
following -adrenoceptor activation. A 6-fold induction of intracellular cAMP was observed when 
differentiated 3T3-L1 adipocytes were treated with 10 M isoproterenol for 10 min (P<0.01) (Fig. 
3B). Treatment with forskolin, a direct stimulator of adenylyl cyclase, for 8 h increased adiponectin 
receptor 2 mRNAs 2-fold (2 M, P<0.01) and 3-fold (10 M, P<0.01) (Fig. 3C), but did not change 
adiponectin receptor 1 mRNAs (data not shown).  
To look for downstream activation of PKA, we used the selective antagonist H-89. After 1 h of 
pre-incubation with 10 M H-89, isoproterenol was added for 16 h. H-89 reversed the stimulatory 
effect of isoproterenol on adiponectin receptor 2 gene expression (Fig. 3D).  
 
3.5. Activation of AMPK inhibits isoproterenol-induced upregulation of adiponectin receptor 2  
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AMP-activated protein kinase (AMPK) is a protein which is activated in response to an increase 
in the ratio of AMP to ATP within the cell and therefore acts as an efficient sensor for the cellular 
energy state. Binding of AMP activates AMPK allosterically and induces phosphorylation the 
threonine residue (Thr-172), the site whose phosphorylation is essential for activity. Reports show 
that isoproterenol can promote the activation of AMPK in adipocytes (Moule et al., 1998; Yin et al. 
2003). Therefore, we also examined the effects of AMPK activation on adiponectin receptor mRNA 
expression. 
Culture of 3T3-L1 adipocytes in the presence of 10 M isoproterenol for 15 min or 1 mM and 2 
mM 5-aminoimidazole-4-carboxamide-riboside (AICAR), a cell-permeable AMPK activator, for 30 
min increased phosphorylation of AMPK at Thr172 but did not affect total AMPK levels (Fig. 3E). 
Adiponectin receptor 2 gene expression was reduced 40% and 60% by 1 mM and 2 mM 
5-aminoimidazole-4-carboxamide-riboside (AICAR), respectively (P<0.01) (Fig. 3F), but 
adiponectin receptor 1 expression was not altered (data not shown). 
3T3-L1 adipocytes were preincubated with 10 M compound C, a selective inhibitor of AMPK, 
for 2 h before treatment with isoproterenol for 24 h. The addition of compound C enhanced the 
stimulatory effect of isoproterenol on adiponectin receptor 2 gene expression (Fig. 3G). 
 
4. Discussion 
 
In the present study, we demonstrate for the first time that the-adrenoceptor agonists 
CL-316,243 and BRL37344 increased TNF-gene expression in rodent epididymal white adipose 
tissue in vivo, and that isoproterenol increased TNF-protein expression in differentiated 3T3-L1 
adipocytes in vitro. The reason TNF- expression is upregulated only in epididymal white adipose 
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tissue may be that lipid metabolism responses to catecholamines differ in epididymal and 
subcutaneous white adipose tissue and brown adipose tissue. Epididymal adipose tissue, a type of 
visceral fat tissue, is lipolytically active compared to subcutaneous fat (Lafontan and Berlan, 2003). 
As high concentrations of (1 mM) free fatty acid, the product of triglyceride hydrolysis, are 
reported to increase TNF- secretion in adipocytes (Nguyen et al., 2005), the abundantly produced 
free fatty acids in epididymal adipose tissue may contribute to the upregulation of TNF-while the 
amount of free fatty acids in subcutaneous adipose tissue is inadequate. Compared with white 
adipose tissue, in which free fatty acids are producted and released to provide energy to other 
organs and tissues in response to catecholamines, in brown adipose tissue free fatty acids are 
oxidized in mitochondia as an energy source for thermogenesis. The concentration of free fatty 
acids in brown adipose tissue may therefore be inadequate to regulate TNF- expression. 
Growing evidence suggests that catecholamines and increased activity of the sympathetic 
nervous system induce insulin resistance (Reaven et al., 1996; Hoieggen et al., 2000; Facchini et 
al., 1996; Maison et al, 2000; Blüher et al., 2000). However, the mechanisms regulating these 
effects are still not completely understood. In our study, TNF-which induces insulin resistance 
(Hotamisligil, 1999), is upregulated by -adrenoceptor agonists. Furthermore, the expression and 
release of adiponectin, an insulin-sensitizing adipokine, were confirmed to be downregulated as 
previously reported (Delporte et al., 2002; Fasshauer et al., 2001). As it is thought that adiponectin 
and TNF- mutually inhibit each other’s production in adipose tissue (Maeda et al., 2001, 2002), 
mutual influences of the two adipokines might exist if -adrenergic stimulation changes the 
regulation of one of them first. The upregulation of TNF- and downregulation of adiponectin by 
-adrenoceptor activation in adipocytes may contribute to the pathogenesis of 
catecholamine-induced insulin resistance.  
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This is also the first report that -adrenoceptor agonists increase adiponectin receptor 2 gene 
expression, but not adiponectin receptor 1, in white and brown adipose tissue of C57BL/6J mice in 
vivo and in differentiated 3T3-L1 adipocytes in vitro. The upregulation of adiponectin receptor 2 
might partly ameliorate insulin resistance by improving adiponectin affinity, but it could not 
completely rescue -adrenoceptor activation-induced insulin resistance. 
As an autocrine factor, adiponectin is reported to promote adipocyte differentiation and lipid 
accumulation, and is proposed to act to maintain adipocyte size and mass at baseline levels (Fu et 
al., 2005). Our results showing that isoproterenol-induced adiponectin receptor 2 upregulation is 
accompanied by a reduced adiponectin expression (Fig. 2B) are consistent with the recent report 
indicating that adiponectin inhibits adiponectin receptor 2 gene expression (Bauche et al., 2006). 
Based on these findings, we propose the upregulation of adiponectin receptor 2 may be a 
consequence of reduced adiponectin. Under the conditions where -adrenergic stimulation 
downregulates adiponectin, we propose that adiponectin receptor 2, which accounts for almost half 
of the total adiponectin receptor expression in fat tissue (Beylot et al., 2006), is locally upregulated 
to compensate for the loss of adiponectin. This response may augment the overall autocrine effect 
of adiponectin, which in turn, helps to reaccumulate lipid lost by lipolysis upon -adrenergic 
stimulation. Thus, the use of the feedback response may facilitate lipid homeostasis of adipocytes. 
The 2-adrenoceptor agonist fenoterol also shows the same stimulatory effect as 3-adrenoceptor 
agonists on adiponectin receptor 2 in adipocytes in vitro (Fig. 3A). As 2,3-adrenoceptor agonists 
are not completely subtype-specific at high concentrations, we confirmed the effects of fenoterol, 
CL-316,243 and BRL37344 at concentrations as low as 100 nM to make sure that the effects are 
through 2 or 3-adrenoceptors, respectively. This finding suggests that the effect of 
2-adrenoceptor agonists on adiponectin receptor 2 may also exist in other organs and tissues where 
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both2-adrenoceptor and adiponectin receptor 2 are present, such as liver and pancreatic islets. 
In adipocytes,-adrenoceptor activation result in the simultaneous stimulation of both PKA and 
AMPK.-adrenergic stimulation-induced AMPK activation in adipocytes is associated with an 
increased AMP/ATP ratio (Koh et al., 2007). Both PKA and AMPK are likely to work in synergy to 
regulate key enzymes involved in metabolism (Cohen and Haride, 1991; Nielsen and Richter, 2003; 
Dyck et al., 1999; Boone et al., 1999; Winder et al., 1997). However, they can also antagonize one 
another, as is the case in the regulation of hormone-sensitive lipase, which regulates lipolysis in 
adipose and muscle tissue (Wat et al., 2005). In our study, we demonstrate that isoproterenol 
regulates adiponectin receptor 2 mainly via activation of adenylyl cyclases and PKA (Fig. 3B-D). 
However, we also found that AMPK activation may inhibit the upregulation of adiponectin receptor 
2 (Fig. 3E-G). The foundings indicate that PKA and AMPK antagonize one another in the 
regulation of adiponectin receptor 2 in adipocytes. 
AMPK is thought to improve insulin sensitivity in muscle and liver (Kahn et al., 2005; Long and 
Zierath, 2006). But it is also reported that activation of AMPK inhibits basal and insulin-stimulated 
glucose uptake and lipogenesis in isolated adipocytes (Gaidhu et al., 2006). Our results show that 
AMPK activation reduces adiponectin receptor 2 gene expression. These data suggest that the 
AMPK signal cascade may oppose insulin effects in fat cells. 
Our study demonstrates that adiponectin receptor 2 is upregulated by -adrenoceptor agonists 
while adiponectin receptor 1 is unchanged. A possible reason underlying this discrepancy may be 
the receptor’s affinity for the various adiponectin forms. Adiponectin receptor 2 is the receptor that 
mediates action of the main full-length form of adiponectin in human plasma (Fruebis et al., 2001; 
Yamauchi et al., 2003). Adiponectin receptor 1 binds globular domain adiponectin, the proteolytic 
cleavage product of full-length adiponectin, reported to be produced by leukocyte elastase secreted 
from activated monocytes and/or neutrophils (Fruebis et al., 2001; Yamauchi et al., 2003; Waki et 
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al., 2005). Since full-length adiponectin newly produced by adipocytes is bound by its high affinity 
receptor 2 (but not receptor 1), adiponectin receptor 2 may play a major role in mediating the 
metabolic effects of adiponectin as an autocrine factor in adipose tissues. 
In our study, adiponectin receptor 2 is also regulated by the adenylyl cyclase stimulator forskolin 
(Fig. 3C) and the AMPK activator 5-aminoimidazole-4-carboxamide-riboside (AICAR) (Fig. 3F), 
while adiponectin receptor 1 is unaffected. It is also reported that growth hormone and PPAR 
agonists upregulate only adiponectin receptor 2 in adipocytes in vitro (Fasshauer et al., 2004; 
Tsuchida et al., 2005). These findings indicate that the regulatory mechanism of adiponectin 
receptor 2 is wholly different from that of adiponectin receptor 1.  
A previous report showed that -adrenoceptor agonists decrease adiponectin gene expression in 
white adipose tissue (Delporte et al., 2002). We demonstrate for the first time that adiponectin is 
also suppressed in brown adipose tissue (Fig. 1A). Although brown adipose tissue, which regulates 
body temperature, plays a different role from white adipose tissue, the effects of 3-adrenoceptor 
agonists CL-316,243 and BRL37344 on the regulation of adiponectin receptor 2 and adiponectin 
are the same in both types of adipose tissue.  
Taken together, we demonstrate in vivo and in vitro that -adrenoceptor agonists downregulate 
adiponectin, but upregulate adiponectin receptor 2 (not receptor 1) and TNF- expression in 
adipocytes. Our results suggest that upregulation of TNF- and downregulation of adiponectin by 
-adrenoceptor activation may contribute to the pathogenesis of catecholamine-induced insulin 
resistance, and that upregulation of adiponectin receptor 2 may be a feedback result of reduced 
adiponectin. 
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Figure legends 
 
Fig. 1. The effects of two -adrenoceptor agonists, CL-316,243 (CL) and BRL37344 (BRL), on 
(A) adiponectin, (B) adiponectin receptor 1, (C) adiponectin receptor 2 and (D) TNF-gene 
expression in epididymal white adipose tissue (EPI WAT), subcutaneous adipose tissue (SC WAT), 
and brown adipose tissue (BAT) in C57BL/6J mice. Mice were injected subcutaneously with two 
doses (2mg/kg) of CL-316,243, BRL37344 or vehicle. Adipose tissues were collected and the 
mRNA expression of adiponectin, adiponectin receptor 1, adiponectin receptor 2 and TNF-were 
quantified by real-time PCR and normalized to 18s rRNA mRNA levels. Results are expressed as 
the means ± S.E.M. Open bars, control (CON) mice (n=8); light gray bars, CL316,243-treated 
mice (n=8); dark gray bars, BRL37344-treated mice (n=7). *P<0.05, **P<0.01 
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Fig. 2. The effect of non-selective -adrenoceptor agonist isoproterenol (ISO) on adiponectin, 
adiponectin receptor 1, and adiponectin receptor 2 gene expression, adiponectin release and 
TNF- protein expression in fully differentiated 3T3-L1 adipocytes. (A) Adiponectin, adiponectin 
receptor 1 and adiponectin receptor 2 gene expression following 16 h treatment of isoproterenol 
(10 M). (B) Time course effects of 10 M isoproterenol on adiponectin and adiponectin receptor 
2 gene expression. (C) Adiponectin release following 24 h treatment with isoproterenol. (D) 
TNF- protein expression following 24 h treatment with isoproterenol. The mRNA expression of 
adiponectin, adiponectin receptor 1 and adiponectin receptor 2 were quantified by real-time PCR 
and normalized to 18s rRNA mRNA levels. Adiponectin release and TNF- protein expression 
were quantified by ELISA and normalized to total protein concentration. Results are expressed as 
the means ± S.E.M.; (n=3) *P<0.05, **P<0.01 
 
Fig. 3. Mechanisms for upregulating adiponectin receptor 2 gene expression by isoproterenol. (A) 
Adiponectin receptor 2 gene expression following 16 h treatments of -adrenoceptor agonist 
dobutamine (DOBU), -adrenoceptor agonist fenoterol (FENO),and -adrenoceptor agonists 
CL-316,243 (CL) and BRL37344 (BRL) (10 M each).(B) Intracellular cAMP following 10 min 
treatment with isoproterenol (ISO). (C) Adiponectin receptor 2 gene expression following 8 h 
treatment with adenylyl cyclase stimulator forskolin (FOR). (D) Effect of PKA inhibitor H-89 on 
isoproterenol-induced adiponectin receptor 2 gene expression. After pre-incubation with H-89 (10 
M) for 1 h, isoproterenol (10 M) was added for 16 h. (E) P-AMPK (Thr172) (top panel) and 
total AMPK protein (bottom panel) following 15 min treatment with isoproterenol (ISO) or 30 min 
with AMPK stimulator 5-aminoimidazole-4-carboxamide-riboside (AICAR). (F) Adiponectin 
receptor 2 gene expression following 16 h treatment with AICAR. (G) Effect of AMPK inhibitor 
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compound C (Comp) on isoproterenol-induced adiponectin receptor 2 gene expression. After 
pre-incubation with compound C (10 M) for 2 h, isoproterenol (10 M) was added for 24 h. 
Intracellular cAMP levels were measured by ELISA. The mRNA expression of adiponectin, 
adiponectin receptor 1 and adiponectin receptor 2 were quantified by real-time PCR and 
normalized to 18s rRNA mRNA levels. P-AMPK and total AMPK proteins were analyzed by 
Western blot using either anti-phospho-AMPK antibody (Thr172) or AMPK antibody. Results are 
expressed as the means ± S.E.M.; (n=3) **P<0.01  
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